



MRC Laboratory
of Molecular
Biology

**CJD Foundation Meeting,
November 2024**



Cryo-EM Structures of Amyloid Filaments from Human Brains

Michel Goedert

Neurodegenerative Diseases

- Alzheimer's disease
- Parkinson's disease
- Dementia with Lewy bodies
- Frontotemporal dementias
- Progressive supranuclear palsy
- Corticobasal degeneration
- Chronic traumatic encephalopathy
- Argyrophilic grain disease
- Globular glial tauopathy
- Multiple system atrophy

● Tau protein ● Beta-amyloid ● Alpha-synuclein

Sporadic and Inherited Diseases

All cases of disease (sporadic or inherited) share the presence of abundant filamentous inclusions in brain cells.

Most cases are sporadic, meaning that they happen in unpredictable ways.

Some cases (<1%) are inherited in a dominant manner, such that on average 50% of the descendants of someone with disease will develop the same disease if they live long enough.




Inherited forms of disease allow one to identify causes of disease.

Known causes lie in changes in the genes that encode the major components of the filamentous inclusions or that increase their production. This is true of tau, APP and alpha-synuclein. It links inclusion formation and causes of disease.



Alzheimer's Disease: Beta-Amyloid and Tau




Extracellular deposition of β -amyloid



Intracellular assembly of tau protein




Abnormal Tau Filaments




Goedert et al., PNAS 1988
Wischik et al., PNAS 1988a,b

Cryo-EM Structures of Paired Helical Tau Filaments




Paired Helical and Straight Filaments




Fitzpatrick et al., Nature 2017
Falcon, Zhang et al., Acta Neuropathologica 2018
Shi et al., Acta Neuropathologica 2021
Hallinan et al., Acta Neuropathologica 2021
Shi, Zhang et al., Nature 2021

Alzheimer Fold



- Alzheimer's disease
- Posterior cortical atrophy
- Some prion protein amyloidoses
- Familial British dementia
- Familial Danish dementia
- Primary age-related tauopathy



Modified from Scheres, Ryskeldi-Falcon, Goedert, Nature 2023

Each sporadic disease with intracellular filamentous amyloid inclusions is characterised by a specific fold, but the same fold can be found in multiple diseases.


Differences in folds are observed between some diseases, not between individuals with a given disease. Thus, for instance, each case of Alzheimer's disease that we have looked at had the same tau fold.

When analysed, in a given brain, the same fold is found in different brain regions.

Non-proteinaceous densities of unknown composition are a common finding.

With the possible exception of TMEM106B filaments, the structurally characterised amyloid filaments are made of a structured core and an unstructured fuzzy coat.

Tau Protein



Tauopathies

3R/4R


- Alzheimer's disease
- Familial British dementia
- Familial Danish dementia
- Primary age-related tauopathy
- Chronic traumatic encephalopathy

3R

- Pick's disease

4R

- Corticobasal degeneration
- Argyrophilic grain disease
- Age-related tau astrogliopathy
- Progressive supranuclear palsy
- Globular glial tauopathy






Modified from Shi, Zhang et al., Nature 2021.



Alzheimer's Disease: Beta-Amyloid and Tau




Extracellular deposition of β -amyloid



Intracellular assembly of tau protein



Structures of Amyloid-beta Filaments from Human Brains




Diffusible, highly bioactive oligomers represent a critical minority of soluble A β in Alzheimer's disease brain

Wei Hong¹  · Zemin Wang¹ · Wen Liu¹ · Tiernan T. O'Malley¹ · Ming Jin¹ · Michael Willem²  · Christian Haass^{2,3,4} · Matthew P. Frosch⁵ · Dominic M. Walsh¹

Acta Neuropathologica 2018


Antibody Lecanemab binds to Amyloid- β 42 Filaments from Brain




Stern et al., Neuron 2023

α -Synuclein

Exons:




Distinct Molecular Conformers (Protein Strains)?




α -Synuclein Assemblies
Lewy Body Diseases
Multiple System Atrophy


Cross-Sections of α -Synuclein Filaments



Type I and Type II α -Synuclein Filaments from MSA Brain




Lewy Fold and MSA Folds






Impact of Amyloid Structures



Scheres, Ryskeldi-Falcon, Goedert, Nature 2023




Assembly of Recombinant Tau (297-391) into Filaments identical to AD PHFs




Assembly of Recombinant Tau (297-391) into Filaments identical to CTE Type II Filaments



Structures in the Assembly Reactions



Structure of the FIA




Tau Proteins of Alzheimer Paired Helical Filaments: Abnormal Phosphorylation of All Six Brain Isoforms

M. Goedert,* M. G. Spillantini,* N. J. Cairns,
and R. A. Crowther*


*Medical Research Council
Laboratory of Molecular Biology
Hills Road
Cambridge CB2 2QH
England

†Department of Neuropathology
Institute of Psychiatry
De Crespigny Park
London SE5 8AF
England




Neuron 1992

Cryo-EM Analysis of PAD12 Tau Filaments



Multiple Rounds of *In Vitro* Seeded Assembly



Our perspective...

- The same protein can adopt many different amyloid folds
 - Yet structures are the same within each brain/disease
 - Highly specific processes in each disease?
 - Amyloid structure provides a ***neuropathological description at the atomic level***
 - And thereby a ***handle to study disease***
- Two scenarios:
 - Distinct structures affect disease processes differently
 - Structure doesn't matter for disease; it is merely a reflection of where they form
- What drives the formation of specific folds in disease?
 - Cofactors/PTMs/cellular environment/other?
 - Study using in vitro assembly, cellular models & animals
- Your favourite model may not be relevant for disease...
 - ***We need better model systems to study this!***

MRC Laboratory of Molecular Biology, Cambridge

M. Huang

T. Katsinelos

S. Lövestam

J. Macdonald

A.G. Murzin

C. Qi

S.H.W. Scheres

G. Stephenson

D. Zhang

Harvard Medical School, Boston

A.M. Stern

D.J. Selkoe

Cambridge University

M.G. Spillantini

Indiana University, Indianapolis

B. Ghetti

**Tokyo Metropolitan Institute of Medical
Science**

M. Hasegawa